Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

78.94 USD +1.28 (+1.65%)
Streaming Delayed Price Updated: 12:44 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Biopharma Leaders Unite to Stand With Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
From GlobeNewswire News Releases
Biopharma Leaders Unite To Stand With Science
Biopharma leaders unite to stand with science. 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
Merck to Present at the Citi 15th Annual BioPharma Virtual Conference 
From Business Wire News Releases
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care 
From Business Wire News Releases
TriRx Pharmaceutical Services acquires MSD Animal Health manufacturing site located in Segré-en Anjou Bleu, France including long-term supply agreement
TriRx Pharmaceutical Services, a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market, today announced that it has finalized an agreement with MSD... 
From PR Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector
From InvestorBrandNetwork
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan 
From Business Wire News Releases
Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers
From ACN Newswire
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Me
KEYTRUDA® in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival in Esophageal Cancer 
From Business Wire News Releases
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
From ACN Newswire
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
From GlobeNewswire News Releases
Merck Animal Health Completes Acquisition of IdentiGEN
Merck Animal Health Completes Acquisition of IdentiGEN 
From Business Wire News Releases
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH 
From Business Wire News Releases
Innovative Technological Advancements Improve Early Cancer Diagnoses
FinancialBuzz.com News Commentary 
From PR Newswire
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio 
From Business Wire News Releases
Merck Announces Second-Quarter 2020 Financial Results
Merck Announces Second-Quarter 2020 Financial Results 
From Business Wire News Releases
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC) 
From Business Wire News Releases
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
FDA Grants Breakthrough Therapy Designation to Merck’s MK-6482 for Certain Patients With Von Hippel-Lindau Disease-Associated RCC 
From Business Wire News Releases
Merck Announces Fourth-Quarter 2020 Dividend
Merck Announces Fourth-Quarter 2020 Dividend 
From Business Wire News Releases
CORRECTION-New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
24/7 Market News- Biotech Headlines
Tags technology science h:worldnews
From EIN Presswire
Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab)...
Oncorus announces clinical trial collaboration with Merck to evaluate the combination of ONCR-177 with KEYTRUDA (pembrolizumab) in Phase 1 Study. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account